Safety Precautions Regarding ParaGard

ParaGard does not protect against HIV/AIDS or other sexually transmitted diseases. You must not use ParaGard if you currently have acute Pelvic Inflammatory Disease (PID) or engage in current behavior suggesting a high risk for PID. ParaGard is also not an option for women who might be pregnant, have a uterus that is abnormally shaped inside, have had a post-pregnancy or post-abortion uterine infection in the past 3 months, have cancer of the uterus or cervix, have unexplained bleeding from the vagina, have an infection in the cervix, have an allergy to any component of ParaGard, have Wilson’s disease or already have an intrauterine contraceptive in the uterus.

Side-effects and complications related to ParaGard

The most common side effects of ParaGard are more substantial and more extended periods for a few months after placement; some women have to spot between periods. For most women, this typically subsides after a few months. However, if your menstrual flow is severe or prolonged, call your healthcare professional. You should also call your healthcare professional without delay if you miss a period as you might be pregnant.

Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard, are a pelvic inflammatory disease (PID), perforation of the uterus, expulsion.

Nothing on this Web Site should be construed as the giving of advice or the making of a recommendation, and it should not be relied on as the basis for any decision or action. It is crucial that you rely only on the advice of a healthcare professional to advise you on your specific situation.

Drugs that protect against sexually transmitted diseases

Drugs that protect against sexually transmitted diseasesParaGard, as we mentioned, doesn’t protect women against sexually transmitted infections. But some other medicines show promising results in dealing with those types of diseases. But none of the solutions you can find on the market are 100% effective in the prevention of such conditions.
The issue with this type of drugs is the attitude with which the medicine approaches this problem. The medical industry leans to the treatment of sexually transmitted diseases rather than their prevention. This brings more money into the industry, and it reduces the cost of research that would go into the discovery of excellent drugs that would prevent such diseases.

About the Author

FEI Women’s Health recently acquired the New Drug Application (NDA) for the Copper T 380A Intrauterine Copper Contraceptive – marketed in the U.S. under the brand name ParaGard® T 380A – from The Population Council in New York, N.Y. FEI specializes in the manufacturing and marketing of intrauterine contraception and has been the exclusive U.S. manufacturer of the Copper T 380A since 1984.